Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5883MR)

This product GTTS-WQ5883MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5883MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15182MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ9515MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ2962MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ1024MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ12500MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ14387MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ9794MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ7044MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW